Enhancing AAV Purification: Strategies For Improved Recovery And Quality For Downstream

In gene therapy manufacturing, the efficient extraction of adeno-associated virus (AAV) material from transfected cell culture lysates is crucial for downstream success. However, challenges such as limited titer production and the difficulty of recovering full capsids complicate this process. This study focuses on optimizing the initial stages of the downstream process using high-titer AAV8 material, employing various analytical methods to ensure quality in ReciBioPharm’s process development. A comprehensive evaluation of ten filter trains from four vendors was conducted, assessing parameters like HCP removal efficacy, DNA breakthrough, titer recovery, turbidity reduction, and throughput capacity.

The standout candidate, Train 2, demonstrated superior performance and will be integrated into ReciBioPharm’s best-in-class AAV platform. This poster presents the findings and methodologies of the filter screening, highlighting Train 2's potential to enhance AAV purification efficiency and its scalability for larger production volumes.